Selected articles
Articles for label Kopecký Jindřich are displayed.. Show all articles
Avelumab and its therapeutic use in uro‑oncology
05/2021 MUDr. Jindřich Kopecký, Ph.D.
Immunotherapy has become an integral part of cancer therapy over the last decade. Treatment of uro-oncological malignancies is no exception. Gradually, nivolumab, pembrolizumab, and ipilimumab have become cornerstones for renal and bladder cancer therapy. Avelumab is becoming another monoclonal antibody that is effective in these cancers. And although it could be said to be another of the molecules. This treatment brings not only the possibility of a wider choice of effective therapy but also, for example, in the case of urothelial carcinoma, a new way of use.
ENTIRE ARTICLE
Immunotherapy has become an integral part of cancer therapy over the last decade. Treatment of uro-oncological malignancies is no exception. Gradually, nivolumab, pembrolizumab, and ipilimumab have become cornerstones for renal and bladder cancer therapy. Avelumab is becoming another monoclonal antibody that is effective in these cancers. And although it could be said to be another of the molecules. This treatment brings not only the possibility of a wider choice of effective therapy but also, for example, in the case of urothelial carcinoma, a new way of use.
Cemiplimab in patients with metastatic or locally advanced cutaneous squamous‑cell carcinoma
05/2020 MUDr. Jindřich Kopecký, Ph.D.
Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin tumors. Surgical intervention remains crucial in the treatment of cSCC. Inoperable or metastatic cSCC is one of the less common but it belongs to incurable diseases. Both systemic preparations (most often cisplatin, 5-fluorouracil) and tyrosine kinase inhibitors are used in systemic treatment. Although a relatively good therapeutic response is achieved with these drugs, their long-term efficacy remains problematic. Cemiplimab is another immunomodulatory drug that targets the PD-1 receptor. The results so far not only have a good therapeutic response, but above all, they maintain their long-term effectiveness. Due to these properties, they have become the drug of choice for inoperable/metastatic cSCC diseases.
ENTIRE ARTICLE
Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin tumors. Surgical intervention remains crucial in the treatment of cSCC. Inoperable or metastatic cSCC is one of the less common but it belongs to incurable diseases. Both systemic preparations (most often cisplatin, 5-fluorouracil) and tyrosine kinase inhibitors are used in systemic treatment. Although a relatively good therapeutic response is achieved with these drugs, their long-term efficacy remains problematic. Cemiplimab is another immunomodulatory drug that targets the PD-1 receptor. The results so far not only have a good therapeutic response, but above all, they maintain their long-term effectiveness. Due to these properties, they have become the drug of choice for inoperable/metastatic cSCC diseases.
Predictive and prognostic factors in metastatic renal carcinoma
04/2020 MUDr. Jindřich Kopecký, Ph.D.
Current treatment algorithms for metastatic renal cell carcinoma are based on the sequential use of drugs. It is therefore advisable to have prognostic and predictive markers available before starting treatment so that the right drug can be chosen for a particular patient with a particular type of kidney tumor. The following article discusses potential biomarkers.
ENTIRE ARTICLE
Current treatment algorithms for metastatic renal cell carcinoma are based on the sequential use of drugs. It is therefore advisable to have prognostic and predictive markers available before starting treatment so that the right drug can be chosen for a particular patient with a particular type of kidney tumor. The following article discusses potential biomarkers.
Metastatic renal cancer immunotherapy versus targeted therapy
03/2019 MUDr. Jindřich Kopecký, Ph.D.
In the last decade, we are witnesses of great development and improvement in renal cancer therapy. Based on better understanding of the mechanisms of pathogenesis and the improvement in immunotherapy, we are able to reach long-term responses. Currently, it is still not clear, if there is a choice of, which drug to use. We do not always have head to head comparisons of drugs. In our conditions is this issue partially artificially simplified due to reimbursement. The following article discusses the current status, advantages and disadvantages of immunotherapy and targeted therapy in renal cancer.
ENTIRE ARTICLE
In the last decade, we are witnesses of great development and improvement in renal cancer therapy. Based on better understanding of the mechanisms of pathogenesis and the improvement in immunotherapy, we are able to reach long-term responses. Currently, it is still not clear, if there is a choice of, which drug to use. We do not always have head to head comparisons of drugs. In our conditions is this issue partially artificially simplified due to reimbursement. The following article discusses the current status, advantages and disadvantages of immunotherapy and targeted therapy in renal cancer.
Current possibilities of immunotherapy for malignant melanoma
03/2018 MUDr. Jindřich Kopecký, Ph.D.; MUDr. Ondřej Kubeček
Thanks to gradually improving understanding of complex interactions between the immune system and cancer and thanks to deeper understanding of molecular interactions between tumour and immune cells at the level of so-called checkpoint inhibitors, there has been a renaissance of immunotherapy as a therapeutic modality in oncology in recent years. The following article focuses on the current status of checkpoint inhibitors for therapy of malignant melanoma and other possibilities for their use in the future.
ENTIRE ARTICLE
Thanks to gradually improving understanding of complex interactions between the immune system and cancer and thanks to deeper understanding of molecular interactions between tumour and immune cells at the level of so-called checkpoint inhibitors, there has been a renaissance of immunotherapy as a therapeutic modality in oncology in recent years. The following article focuses on the current status of checkpoint inhibitors for therapy of malignant melanoma and other possibilities for their use in the future.
Immune‑related adverse events
02/2017 MUDr. Aneta Kyllarová, MUDr. Ondřej Kubeček, MUDr. Jindřich Kopecký, Ph.D.
Immunotherapy has gradually become a part of standard treatment of selected solid tumours since 2011. The spectrum of malignancies suitable for this treatment modality has been increasing since then. Consequently, the amount of patients treated with immunotherapy has been rising. Despite undeniable efficacy of this modality, we are facing a new spectrum of adverse effect distinct from conventional therapies (radiotherapy, chemotherapy). The aim of this article is to provide a brief review on the most common adverse effects of immunotherapy and their management. We aim to provide physicians, who do not routinely deal with these drugs, with some basic information, so that they are able to manage some minor toxicities or refer the patients to appropriate cancer centre.
ENTIRE ARTICLE
Immunotherapy has gradually become a part of standard treatment of selected solid tumours since 2011. The spectrum of malignancies suitable for this treatment modality has been increasing since then. Consequently, the amount of patients treated with immunotherapy has been rising. Despite undeniable efficacy of this modality, we are facing a new spectrum of adverse effect distinct from conventional therapies (radiotherapy, chemotherapy). The aim of this article is to provide a brief review on the most common adverse effects of immunotherapy and their management. We aim to provide physicians, who do not routinely deal with these drugs, with some basic information, so that they are able to manage some minor toxicities or refer the patients to appropriate cancer centre.